1. Approaches for monitoring and treating cardiomyopathy among cancer survivors following anthracycline or thoracic radiation treatment
- Author
-
Arash Delavar, Catherine Boutros, Dana Barnea, Wendy L. Schaffer MD, and Emily S. Tonorezos
- Subjects
Preventive cardiology ,Cancer survivorship ,Anthracycline ,Radiation therapy ,Cardiomyopathy ,Medical decision making ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Anthracycline chemotherapy and thoracic radiation therapy (RT) are known causes of cardiomyopathy among cancer survivors, however, management guidelines for this population are lacking. In this study we describe our single institution management approach for cancer survivors with low left ventricular ejection fraction (LVEF) secondary to cancer treatment. Methods We conducted a retrospective descriptive study of childhood and young adult (CAYA) cancer survivors in the Adult Long-Term Follow-Up Clinic at Memorial Sloan Kettering Cancer Center enrolled between November 2005 and July 2019. Those included were treated with anthracycline and/or thoracic RT as a part of their cancer therapy and had recorded a LVEF of
- Published
- 2022
- Full Text
- View/download PDF